Adding to its existing WFI-quality water buffer manufacturing capabilities, Avantor said the investments will dramatically increase its capacity to support biopharma manufacturers worldwide, especially as the Polish site was designed with built-in flexibility to expand capacity as the business grows.

The additional capacity at both sites will enhance the quality of its services, the company added. This, it said, can help customers in the biopharma industry reduce the cost and time to manufacture therapies, including monoclonal antibodies and vaccines, at scale and thus enable greater workflow efficiencies and increase speed to market of new and existing therapies.

Ger Brophy, executive vice president of biopharma production at Avantor, said the CDMO’s investments in its global hydration offering will allow it to strengthen its cGMP chemical manufacturing capability in Europe and the US. Alongside Europe, the Gliwice facility also supports customers in Asia. Upon completion, the Aurora plant will offer expanded support to North America.

Author: Dede Williams, Freelance Journalist